Clearside Biomedical 2017 Cowen Health Care Conference

Clearside Biomedical presented its suprachoroidal space (SCS) platform for targeted retinal and choroidal disease therapy at the 2017 Cowen Health Care Conference. The company showcased positive Phase 2 clinical data in retinal vascular disease and ocular inflammatory disease, with Phase 3 trials underway in retinal vein occlusion and uveitis, targeting diseases including diabetic macular edema and wet AMD.